Search results for "Tolerability"

showing 10 items of 372 documents

Solifenacin in the Elderly: Results of an Observational Study Measuring Efficacy, Tolerability and Cognitive Effects.

2015

<b><i>Introduction:</i></b> The study aimed to evaluate the efficacy and safety of solifenacin in older patients with overactive bladder (OAB). <b><i>Materials and Methods:</i></b> Observational data on patients aged ≥70 years and the prescribed flexible dose of solifenacin for OAB were collected at 294 offices of German general practitioners. Baseline and week 12 data included type and severity of OAB symptoms, adverse events, quality of life, and change in cognitive function per Mini Mental State Examination (MMSE). <b><i>Results:</i></b> Mean age of 774 patients was 78 ± 6 years. A decrease was observed in all OAB sy…

Malemedicine.medical_specialtyUrinary urgencyUrology030232 urology & nephrologyUrologyMuscarinic Antagonistsurologic and male genital diseases03 medical and health sciences0302 clinical medicineCognitionQuality of lifeInternal medicineGermanyMedicineHumansAdverse effectAgedAged 80 and overMini–Mental State ExaminationSolifenacinmedicine.diagnostic_testbusiness.industryUrinary Bladder OveractiveSolifenacin SuccinateMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsTreatment OutcomeOveractive bladderTolerability030220 oncology & carcinogenesisQuality of LifeObservational studyFemalemedicine.symptombusinessCognition Disordersmedicine.drugUrologia internationalis
researchProduct

Salvage Therapy With Oral Metronomic Cyclophosphamide and Methotrexate for Castration refractory Metastatic Adenocarcinoma of the Prostate Resistant …

2011

Objective To investigate the activity and toxicity of metronomic chemotherapy with low-dose oral cyclophosphamide (CTX) and methotrexate (MTX) in patients with metastatic CRPC that progresses after docetaxel. Patients with castration-resistant prostate cancer (CRPC) that progresses after docetaxel may benefit from receiving further chemotherapy. Methods Patients were treated with CTX 50 mg/d p.o. plus MTX 2.4 mg p.o. twice per week without rest periods. All patients received simultaneous luteinizing hormone-releasing hormone analogue. Prostate-specific antigen (PSA) response was defined as a 50% reduction on 2 evaluations at least 4 weeks apart. Objective response was measured according to …

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentSalvage therapyPhases of clinical researchAdministration OralAntineoplastic AgentsDocetaxelAdenocarcinomaGastroenterologyCyclophosphamide docetaxel methotrexate metronomic chemotherapy prostate carcinomaSettore MED/24 - UrologiaProstate cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansTreatment FailureCyclophosphamideSalvage TherapyChemotherapyLeukopeniabusiness.industryProstatic Neoplasmsmedicine.diseaseMetronomic ChemotherapySurgeryMethotrexateDocetaxelTolerabilityAdministration MetronomicTaxoidsmedicine.symptombusinessmedicine.drug
researchProduct

Effectiveness and Tolerability of Fixed-Dose Combination Enalapril plus Nitrendipine in Hypertensive Patients Results of the 3-Month Observational, P…

2009

Background and objective: Monotherapy with any class of antihypertensive drug effectively controls blood pressure (BP) in only about 50% of patients. Consequently, the majority of patients with hypertension require combined therapy with two or more medications. This study aimed to evaluate the effectiveness (systolic BP [SBP]/diastolic BP [DBP] control) and tolerability of the fixed-dose combination enalapril/nitrendipine 10 mg/20 mg administered as a single daily dose in hypertensive patients. Methods: This was a post-authorization, multicentre, prospective, observational study conducted in primary care with a 3-month follow-up. Patients throughout Spain with uncontrolled hypertension (>= …

Malemedicine.medical_specialtymedicine.drug_classSystolic hypertensionFixed-dose combinationPopulationAngiotensin-Converting Enzyme InhibitorsBlood PressureEssential hypertensionEnalaprilInternal medicinemedicineProduct Surveillance PostmarketingHumansPharmacology (medical)EnalaprilProspective StudieseducationAntihypertensive drugAntihypertensive Agentseducation.field_of_studyDose-Response Relationship DrugPrimary Health Carebusiness.industryNitrendipineGeneral MedicineMiddle Agedmedicine.diseaseCalcium Channel BlockersDrug CombinationsBlood pressureTolerabilityAnesthesiaHypertensionFemalebusinessmedicine.drug
researchProduct

Evidence for reading improvement following tDCS treatment in children and adolescents with Dyslexia.

2016

Purpose There is evidence that non-invasive brain stimulation transitorily modulates reading by facilitating the neural pathways underactive in individuals with dyslexia. The study aimed at investigating whether multiple sessions of transcranial direct current stimulation (tDCS) would enhance reading abilities of children and adolescents with dyslexia and whether the effect is long-lasting. Methods Eighteen children and adolescents with dyslexia received three 20-minute sessions a week for 6 weeks (18 sessions) of left anodal/right cathodal tDCS set at 1 mA over parieto-temporal regions combined with a cognitive training. The participants were randomly assigned to the active or the sham tre…

Malemedicine.medical_treatmentAudiologyTranscranial Direct Current StimulationFunctional LateralityDevelopmental psychologycognitive trainingDyslexia0302 clinical medicineReading (process)Childmedia_commonneurology (clinical)Cerebral CortexTranscranial direct-current stimulation05 social sciencesCognitive trainingparieto-temporal regionsCognitive behavioral therapyTreatment OutcomeTolerabilityFemaleBrain stimulation cognitive training parieto-temporal regions Adolescent Cerebral Cortex Cognitive Behavioral Therapy Double-Blind Method Dyslexia Functional Laterality Transcranial Direct Current Stimulation Treatment Outcome ReadingPsychologymedicine.medical_specialtyAdolescentmedia_common.quotation_subjectbrain stimulation050105 experimental psychologyNObrain stimulation; cognitive training; parieto-temporal regions; adolescent; analysis of variance; cerebral cortex; child; cognitive therapy; double-blind method; dyslexia; female; functional laterality; humans; male; transcranial direct current stimulation; treatment outcome; reading; medicine (all); neurology; developmental neuroscience; neurology (clinical)03 medical and health sciencesSettore MED/39 - NEUROPSICHIATRIA INFANTILEDouble-Blind Methodmental disordersmedicineHumans0501 psychology and cognitive sciencesmedicine (all)parieto-temporal regionAnalysis of VarianceCognitive Behavioral TherapyneurologyDyslexiamedicine.diseaseWord lists by frequencydevelopmental neuroscienceReadingBrain stimulationcognitive therapy030217 neurology & neurosurgeryRestorative neurology and neuroscience
researchProduct

Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (C…

2019

Background and aims Limited data are available on the effectiveness and tolerability of direct-acting antivirals (DAAs) therapies in the real world for HCV-infected patients with comorbidities. This study aimed to describe the effectiveness of OBV/PTV/r +/- DSV (3D/2D regimen) with or without ribavirin (RBV) in HCV or HCV/HIV co-infected patients with GT1/GT4 and CKD (IIIb-V stages), including those under hemodialysis and peritoneal dialysis in routine clinical practice in Spain in 2015. Material and methods Non-interventional, retrospective, multicenter data collection study in 31 Spanish sites. Socio-demographic, clinical variables, study treatment characteristics, effectiveness and toler…

Malemedicine.medical_treatmentHIV InfectionsHepacivirus0302 clinical medicine:Infections::Virus Diseases::Hepatitis Viral Human::Hepatitis C::Hepatitis C Chronic [DISEASES]ribavirina2-Naphthylaminemediana edad:virosis::infecciones por virus ARN::infecciones por Retroviridae::infecciones por Lentivirus::infecciones por VIH [ENFERMEDADES]ancianoSulfonamidesCoinfectionfarmacoterapiaLiver Diseasesvirus diseasesValineInfeccions per VIH - TractamentCirrhosisNephrology/drug therapyMedicine030211 gastroenterology & hepatologyDrug Therapy Combinationinsuficiencia renalmedicine.medical_specialty:virosis::hepatitis viral humana::hepatitis C::hepatitis C crónica [ENFERMEDADES]GenotypeProlineSciencecompuestos macrocíclicosSurgical and Invasive Medical ProceduresGastroenterology and HepatologyAntiviral AgentsMicrobiologyUrinary System ProceduresPeritoneal dialysis03 medical and health sciencesDrug TherapyHumansLost to follow-upRenal Insufficiency ChronicUracilAgedRetrospective StudiesFlavivirusesanilidasOrganismsOrgan Transplantationmedicine.diseasedigestive system diseasesRegimenchemistryHIV-1Malalties del ronyóCarbamatesgenotipoCyclopropanesRNA virusesantivíricosSustained Virologic ResponsePhysiologyhumanoschemistry.chemical_compoundChronic Kidney DiseaseMedicine and Health SciencesRenal TransplantationAnilidesRenal Insufficiency030212 general & internal medicinePathology and laboratory medicinecoinfecciónMultidisciplinaryKidney diseasesHepatitis C virus:Infections::Infections::Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::Infections::Virus Diseases::HIV Infections [DISEASES]resultado del tratamientoQR:Infections::Coinfection [DISEASES]Middle AgedMedical microbiologyHepatitis CTreatment OutcomeInfectious DiseasesTolerabilityResearch DesigncarbamatosVirusesFemaleHemodialysisPathogensVIH-1Research ArticleGlomerular Filtration RateMacrocyclic CompoundsClinical Research DesignLactams MacrocyclicResearch and Analysis MethodssulfonamidasRenal DialysisInternal medicineRibavirinMedical DialysismedicineDialysisTransplantationRenal Physiology/tratamiento farmacológicoRitonavirBiology and life sciencesbusiness.industryRibavirinestudios retrospectivosViral pathogensHepatitis C ChronicHepatitis virusesMicrobial pathogens:enfermedades parasitarias::coinfección [ENFERMEDADES]Spaindiálisis renalCo-InfectionsPhysical therapyinfecciones por VIHAdverse EventsbusinessHepatitis C - TractamenturaciloKidney diseasePLoS ONE
researchProduct

Managing hepatitis C in liver transplant patients with recurrent infection

2009

Tim Zimmermann1, Gerd Otto2, Marcus Schuchmann11Department of Internal Medicine, 2Transplantation Surgery, University of Mainz, GermanyAbstract: Hepatitis C virus (HCV) reinfection after liver transplantation (LT) and recurrent hepatitis C often lead to recurrent cirrhosis (RC). RC is one of the most frequent complications resulting in organ failure and early death after LT in HCV-positive patients with reported 5-year rates from 20% to 40%. As HCV-cirrhosis is one of the leading indications for LT, the therapeutic management is a central issue. To date, the best available therapy is a combination of pegylated interferon + ribavirin in patients with established recurrent hepatitis C proven …

Medicine (General)medicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatmentLiver transplantationmedicine.disease_causeGastroenterologychemistry.chemical_compoundR5-920Pegylated interferonInternal medicinemedicineTransplantationmedicine.diagnostic_testbusiness.industryRibavirinHepatitis Cmedicine.diseaseSurgerychemistryTolerabilityLiver biopsyStatistics Probability and Uncertaintybusinessmedicine.drugTransplant Research and Risk Management
researchProduct

Comparison of a New Reduced Toxicity Myeloablative Treosulfan and Fludarabine Preparative Regimen with Myeloablative Busulfan or Melphalan in Combina…

2019

Background The best preparative regimen for the growing number of older acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients undergoing allogeneic hematopoietic cell transplantation (HCT) from matched related (MRD) or unrelated donors (MUD) remains undefined. A large randomized phase III trial (MC-FludT.14/L study: ClinicalTrials.gov Identifier: NCT00822393) recently demonstrated that myeloablative intravenous (IV) treosulfan (10 g/m² IV on days -4 to -2) in combination with fludarabine (TreoFlu) improves outcome in older and/or comorbid patients with AML in complete remission (CR) or MDS compared with the reference reduced intensity busulfan (0.8 mg/kg IV in 6-hour inte…

Melphalanmedicine.medical_specialtybusiness.industryImmunologyMedizinCell BiologyHematologyTreosulfanBiochemistryFludarabineTransplantationRegimenTolerabilityhemic and lymphatic diseasesInternal medicinemedicinebusinessBusulfanmedicine.drugPreparative Regimen
researchProduct

Pegylated liposomal doxorubicin in the management of ovarian cancer

2014

Ovarian cancer is the leading cause of death among gynecological tumors. Carboplatin/paclitaxel represents the cornerstone of front-line treatment. Instead, there is no consensus for management of recurrent/progressive disease, in which pegylated liposomal doxorubicin (PLD) ± carboplatin is widely used. We performed a systematic review and metaanalysis to evaluate impact of PLD-based compared with no-PLD-based regimens in the ovarian cancer treatment. Data were extracted from randomized trials comparing PLD-based treatment to any other regimens in the January 2000-January 2013 time-frame. Study end-points were overall survival (OS), progression free survival (PFS), response rate (RR), CA125…

MetaanalysiOncologyCancer Researchmedicine.medical_specialtyendocrine system diseasesPharmacologyarian cancerDisease-Free SurvivalPolyethylene Glycolslaw.inventionchemistry.chemical_compoundRandomized controlled triallawOvPegylated liposomal doxorubicinInternal medicinemedicineHumansProgression-free survivalSystemic chemotherapyProportional Hazards ModelsRandomized Controlled Trials as TopicOvarian NeoplasmsPharmacologyAntibiotics Antineoplasticbusiness.industryProportional hazards modelHazard ratiomedicine.diseaseCarboplatinTreatment OutcomeOncologychemistryTolerabilityDoxorubicinClinical StudyMolecular MedicineFemaleRandomized clinical trialbusinessOvarian cancerProgressive diseaseCancer Biology & Therapy
researchProduct

Current and future challenges in HCV: insights from an Italian experts panel

2017

Background: The recent availability of direct acting antiviral drugs (DAAs) has drastically changed hepatitis C virus (HCV) treatment scenarios, due to the exceedingly high rates of sustained virological response (SVR) and excellent tolerability allowing for treatment at all disease stages. Methods: A panel of Italian experts was convened twice, in November 2016 and January 2017, to provide further support on some open issues and provide guidance for personalized HCV care, also in light of forthcoming regimens. Results and conclusions: Treatment recommendations issued by international and national liver societies to guide clinicians in the management of HCV infection are constantly updated …

Microbiology (medical)medicine.medical_specialtySettore MED/17 - Malattie InfettiveDisease stagesComorbidityAntiviral AgentsComorbiditiesVirological response03 medical and health sciences0302 clinical medicineComorbidities; DAAs; HCV; Treatment; Microbiology (medical); Infectious DiseasesmedicineHumans030212 general & internal medicineIntensive care medicineDAAHigh rateComorbidities; DAAs; HCV; Treatmentbusiness.industryDAAsGeneral MedicineHepatitis Cmedicine.diseaseHepatitis CVirologyTreatmentInfectious DiseasesItalyTolerabilityComorbidities; DAAs; HCV; Treatment; Comorbidity; Hepatitis C; Humans; Italy; Antiviral AgentsHealthcare settingsHCV030211 gastroenterology & hepatologyComorbiditiebusinessDirect acting
researchProduct

Evaluation of the anaesthetic properties and tolerance of 1:100,000 articaine versus 1:100,000 lidocaine. : a comparative study in surgery of the low…

2011

Objectives: To evaluate the anaesthetic properties and tolerance of articaine versus lidocaine at equal vasoconstrictor concentration. Study Design: A total of 96 male and female patients who underwent surgical treatment of the lower third molar participated. Patients were randomly assigned to articaine hydrochloride with epinephrine 1:100,000 and lidocaine hydrochloride with epinephrine 1:100,000. The variables analysed were latency period, duration of anaesthetic effect, tolerance and adverse reactions. Results: Both the latency period and the duration of anaesthetic effect were greater for articaine, although the differences were not statistically significant. Latency: mean difference of…

MolarAdultMalemedicine.medical_specialtyLidocaineAdolescentAnesthesia DentalLidocaine HydrochlorideCarticaineArticaineArticaine HydrochlorideYoung AdultClinical and Experimental DentistrymedicineHumansSingle-Blind MethodAnesthetics LocalAdverse effectGeneral Dentistrybusiness.industryLidocaineMiddle Aged:CIENCIAS MÉDICAS [UNESCO]SurgeryEpinephrineOtorhinolaryngologyTolerabilityAnesthesiaUNESCO::CIENCIAS MÉDICASSurgeryResearch-ArticleFemaleMolar Thirdbusinessmedicine.drug
researchProduct